Spironolactone vs Amiloride for Resistant Hypertension
JAMA · 17.06.2025 · 333 (23) · 2073
DOI: 10.1001/jama.2025.5129 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift JAMA, erschienen am 17.06.2025. Verfasst von Chan Joo Lee und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Amiloride, Antihypertensive Agents, Diuretics, Hypertension. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Amiloride has been proposed as an alternative to spironolactone for treating resistant hypertension. However, no randomized clinical trials have compared the efficacy of spironolactone and amiloride in patients with resistant hypertension.
Objective
To determine whether amiloride is noninferior to spironolactone in reducing home-measured systolic blood pressure (SBP) in patients with resistant hypertension. Design, Setting, and Participants Prospective, open-label, blinded end-point randomized clinical trial conducted at 14 sites in South Korea. From November 16, 2020, to February 29, 2024, 118 patients with home SBP of 130 mm Hg or greater after a 4-week run-in period with a fixed-dose triple medication combination (angiotensin receptor blocker, calcium channel blocker, and thiazide) were enrolled.
Intervention
Patients were randomized in a 1:1 ratio to receive 12.5 mg/d of spironolactone (n = 60) or 5 mg/d of amiloride (n = 58). If home SBP remained 130 mm Hg or greater and serum potassium was less than 5.0 mmol/L after 4 weeks, dosages were increased to 25 mg/d and 10 mg/d, respectively. Main Outcomes and Measures The primary end point was the between-group difference in home SBP change at week 12, with a noninferiority margin of −4.4 mm Hg for the lower bound of the confidence interval. Secondary end points included achievement rates of home- and office-measured SBP of less than 130 mm Hg.
Results
The median age of the study population was 55 years, with 70% male. There were no differences between groups in demographic characteristics other than use of α-blockers (8.6% in the amiloride group and 0% in the spironolactone group). The mean baseline home SBPs were 141.5 (SD, 7.9) mm Hg and 142.3 (SD, 8.5) mm Hg in the amiloride and spironolactone groups, respectively. At week 12, mean home SBP measurements were changed from baseline by −13.6 (SD, 8.6) mm Hg and −14.7 (SD, 11.0) mm Hg in the amiloride and spironolactone groups, respectively (between-group difference in change, −0.68 mm Hg; 90% CI, −3.50 to 2.14 mm Hg), with amiloride demonstrating noninferiority to spironolactone. Home-measured achievement rates of SBP less than 130 mm Hg in the amiloride and spironolactone groups were 66.1% and 55.2%, respectively, and office-measured achievement rates of SBP less than 130 mm Hg were 57.1% and 60.3%, respectively, with no difference between the 2 groups. One case of hyperkalemia-related discontinuation occurred in the amiloride group, with no cases of gynecomastia in either group. Conclusions and Relevance Amiloride was noninferior to spironolactone in lowering home SBP, suggesting that it could be an effective alternative for treatment of resistant hypertension. Trial Registration ClinicalTrials.gov Identifier: NCT04331691
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, Bucheon St Mary's Hospital and the Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, Catholic University of Korea, Seoul, R…
- Division of General Internal Medicine, Department of Internal Medicine, Severance Hospital, Seoul, Republic of Korea.
- Department of Cardiology in Internal Medicine, Chungnam National University College of Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea.
- Department of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea.
- Division of Cardiology, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea.
Zitieren
APA
Lee, C. J., Ihm, S. H., Shin, D. H., Jeong, J. O., Kim, J. H., Chun, K. H., Ryu, J., Lee, H. Y., Choi, S., Lee, E. M., Choi, J. H., Kim, K. I., Shin, J., Pyun, W. B., Kim, D. H., Park, S., & Williams, B. (2025). Spironolactone vs Amiloride for Resistant Hypertension. JAMA, 333(23), 2073. https://doi.org/10.1001/jama.2025.5129
Vancouver
Lee CJ, Ihm SH, Shin DH, Jeong JO, Kim JH, Chun KH, et al. Spironolactone vs Amiloride for Resistant Hypertension. JAMA. 2025;333(23):2073. doi:10.1001/jama.2025.5129
BibTeX
@article{Lee2025,
author = {Lee, Chan Joo and Ihm, Sang-Hyun and Shin, Dong-Ho and Jeong, Jin-Ok and Kim, Ju Han and Chun, Kyeong-Hyeon and Ryu, JiWung and Lee, Hae-Young and Choi, Seonghoon and Lee, Eun Mi and Choi, Jung Hyun and Kim, Kwang-Il and Shin, Jinho and Pyun, Wook Bum and Kim, Dae-Hee and Park, Sungha and Williams, Bryan},
title = {Spironolactone vs Amiloride for Resistant Hypertension},
journal = {JAMA},
year = {2025},
volume = {333},
number = {23},
pages = {2073},
doi = {10.1001/jama.2025.5129}
}
EUVIMED